ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Black Diamond Therapeutics, Inc. ?
1
The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 21.34 MM
- ROCE(HY) Highest at 19.23%
- RAW MATERIAL COST(Y) Fallen by 0% (YoY)
2
With ROE of 17.04%, it has a very attractive valuation with a 0.99 Price to Book Value
- Over the past year, while the stock has generated a return of 27.38%, its profits have risen by 129.4% ; the PEG ratio of the company is 0
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 2.14% over the previous quarter.
4
Market Beating Performance
- The stock has generated a return of 27.38% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Black Diamond Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Black Diamond Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Black Diamond Therapeutics, Inc.
30.36%
-0.77
75.91%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
134.56%
EBIT Growth (5y)
17.18%
EBIT to Interest (avg)
-77.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0.51
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
97.86%
ROCE (avg)
0
ROE (avg)
0.72%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.99
EV to EBIT
-0.60
EV to EBITDA
-0.58
EV to Capital Employed
1.24
EV to Sales
-0.10
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
-207.40%
ROE (Latest)
17.04%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 21.34 MM
ROCE(HY)
Highest at 19.23%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET SALES(9M)
Higher at USD 70 MM
NET PROFIT(9M)
Higher at USD 37.48 MM
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Black Diamond Therapeutics, Inc.
Net Sales
At USD 70 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Profit
At USD 37.48 MM has Grown at 169.81%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 21.34 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 70 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD 37.48 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
